Articles from Veradermics, Incorporated

Veradermics, Incorporated (“Veradermics”), (NYSE: MANE) a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for common aesthetic and dermatological conditions, today announced the closing of its previously announced upsized initial public offering of 17,339,294 shares of its common stock at an initial public offering price of $17.00 per share, including 2,261,647 shares sold pursuant to the exercise in full of the underwriters’ option to purchase additional shares. The gross proceeds from the offering were approximately $294.8 million, before deducting underwriting discount and commissions and estimated offering expenses. All of the shares were sold by Veradermics. Veradermics shares began trading on the New York Stock Exchange on February 4, 2026 under the ticker symbol “MANE”.

Veradermics, Incorporated (“Veradermics”), (NYSE: MANE) a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for common aesthetic and dermatological conditions, today announced the pricing of its upsized initial public offering of 15,077,647 shares of its common stock at an initial public offering price of $17.00 per share. All of the shares are being offered by Veradermics. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $256.3 million. Veradermics’ common stock is expected to begin trading on the New York Stock Exchange on February 4, 2026 under the ticker symbol “MANE”. The offering is expected to close on February 5, 2026, subject to the satisfaction of customary closing conditions. In addition, Veradermics has granted the underwriters a 30-day option to purchase up to an additional 2,261,647 shares of common stock at the initial public offering price, less underwriting discounts and commissions.